Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common type of primary liver malignancy and ranks third in the world's leading causes of cancer death ([@ref-5]). The highest incidence rates of HCC worldwide are in East Asia and sub-Saharan Africa, with over 20 per 100,000 individuals ([@ref-18]; [@ref-45]). According to data from the Surveillance, Epidemiology, and End Results (SEER) program in the United States, HCC incidence remains relatively low compared to other primary cancers ([@ref-28]). However, the incidence rate has risen nearly fivefold from 1.4 to 6.7 per 100,000 individuals over the past decades ([@ref-14]; [@ref-42]). Regarding gender, HCC prevalence worldwide in males is higher than in females. The sex ratio in HCC varies from 4:1 to 2:1, depending on geographical area ([@ref-22]; [@ref-27]). Due to its extensive prevalence, HCC puts a substantial economic burden on the public health and medical system, whether in developed or developing countries.

Academic journals have published a large number of papers in HCC research since the past decade. However, no attempts have been made to analyse the data on publications systematically. Bibliometric analysis is defined as a quantitative analysis combining mathematical and statistical methods ([@ref-30]), and is a good choice for assessing trends in research activites ([@ref-12]). Moreover, bibliometric analysis focuses on the metrological characteristics of research literatures within a certain field ([@ref-15]), which helps investigators to grasp the development characteristics in this field over time and guide their follow-up work. In recent years, an increasing number of bibliometric studies have been published in high-impact medical journals ([@ref-1]; [@ref-2]; [@ref-3]; [@ref-4]; [@ref-7]; [@ref-25]). Journals have also gradually shifted from publishing only conventional research to including bibliometric research ([@ref-41]).

The present study systematically evaluated HCC research from 2008 to 2017. We aimed to identify the mode of publications, construct research collaboration networks, and assess research trends and frontiers by time.

Materials & Methods
===================

Data source and search strategy
-------------------------------

Literature retrieval was done online through the Science Citation Index-Expanded (SCI-E) of the Web of Science Core Collection (WoSCC) on March 31, 2018. All searches were done within the same day, to avoid the bias caused by the daily database updates. The search terms were used as follows: = ("hepatocellular carcinoma\*") OR = ("hepatic cell carcinoma\*") OR = ("liver cell carcinoma\*") OR = ("liver carcinoma rupture") OR = ("primary liver cancer\*") OR = ("primary liver carcinoma\*") OR = ("malignant hepatoma\*") OR = ("hepatocarcinoma\*") OR = ("hepatoma\*") AND Language= English. In the present study, only original and review papers were included.

Data collection
---------------

Raw data from WoSCC were initially downloaded and verified by two authors (YZ and YM) independently. The data were then imported into Excel 2016 (Redmond, WA, USA) and CiteSpace IV (Drexel University, Philadelphia, PA, USA), and systematically analysed. Any differences were unified by discussion.

Statistical methods
-------------------

The WoSCC literature analysis report was used to analyse publication characteristics, including countries/regions, institutes, authors, journal sources, citation counts, number of annual publications, impact factor and H-index. The impact factor is an indicator that reflects the average number of yearly citations for recent papers published in the journal ([@ref-17]). It is used to assess the quantity of research output in most bibliometric studies. H-index is a measure calculating both the productivity and citation impact per publication of a country, institute, scholar, and so forth ([@ref-11]). It usually serves as an indicator for assessing the quality of scientific output.
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CiteSpace IV was used to analyse the association between journals, explore collaboration networks between authors/institutes/countries, identify co-cited authors/references, capture keywords with strong citation bursts, and construct visualization maps of all items mentioned above. In the present study, the individual network was derived from the 50 most highly cited papers in a one-year slice ([@ref-9]). Moreover, we used the TF-IDF weighting to analyse the contents of each cluster. TF-IDF, an abbreviation of term frequency-inverse document frequency, is a statistical algorithm reflecting how significant a word to a corpus of documents ([@ref-31]).

Results
=======

Annual publications and growth forecast
---------------------------------------

In total, 24,331 papers ([Fig. 1](#fig-1){ref-type="fig"}, [Fig. S1](#supp-5){ref-type="supplementary-material"}) matched the retrieval criteria, including 93 systematic reviews, 541 meta-analysis, and 132 systematic review and meta-analysis. The number of publications by year was presented in [Fig. 2A](#fig-2){ref-type="fig"}, where the overall trend consistently kept rising from 1,348 articles in 2008 to 3,572 articles in 2017.

![Flow chart of hepatocellular carcinoma research inclusion.](peerj-06-5477-g001){#fig-1}

![Publication outputs and growth forecast.\
(A) The annual number of publication in hepatocellular carcinoma research from 2008 to 2017. (B) The polynomial curve fitting of publication growth in hepatocellular carcinoma research.](peerj-06-5477-g002){#fig-2}

The polynomial curve fitting of publication growth in HCC research showed a significant correlation (the coefficient of determination (*R*^2^) = 0.9985) between publication year and number of publications ([Fig. 2B](#fig-2){ref-type="fig"}). Through curve fitting, the number of publications was estimated to reach 3,660 in 2018.

Distribution of journals
------------------------

In total, 1,681 academic journals ([Dataset S1](#supp-1){ref-type="supplementary-material"}) have published papers in HCC research. [Table 1](#table-1){ref-type="table"} presented the top 15 journals contributing to HCC research. *Oncotarget* (impact factor (IF) 2016 = 5.168), published the most papers (852 publications, 3.50%), followed by *PLOS ONE* (IF 2016 = 2.806; 794 publications; 3.26%), *World Journal of Gastroenterology* (IF 2016 = 3.365; 705 publications; 2.90%), and *Hepatology* (IF 2016 = 13.246; 500 publications; 2.06%).

10.7717/peerj.5477/table-1

###### The top 15 journals that published articles in hepatocellular carcinoma research.

![](peerj-06-5477-g009)

  **Rank**   **Journal title**                            **Country**     **Count**   **Percent**   **IF 2016**
  ---------- -------------------------------------------- --------------- ----------- ------------- -------------
  1          Oncotarget                                   United States   852         3.50          5.168
  2          PLOS One                                     United States   794         3.26          2.806
  3          World Journal of Gastroenterology            United States   705         2.90          3.365
  4          Hepatology                                   United States   500         2.06          13.246
  5          Oncology Reports                             Greece          423         1.74          2.662
  6          Tumor Biology                                England         413         1.70          3.650
  7          Hepatology Research                          Japan           365         1.50          2.602
  8          Oncology Letters                             Greece          351         1.44          1.390
  9          Journal of Hepatology                        Netherlands     327         1.34          12.486
  10         Hepato-Gastroenterology                      Germany         283         1.16          NA
  11         Journal of Gastroenterology and Hepatology   Australia       279         1.15          3.452
  12         Liver International                          Denmark         265         1.09          4.116
  13         Cancer Letters                               Netherlands     259         1.06          6.375
  14         Scientific Reports                           England         259         1.06          4.259
  15         BMC Cancer                                   England         244         1.00          3.288

[Figure 3](#fig-3){ref-type="fig"} displayed the dual-map overlay of journals. The left and right sides corresponded to the citing and cited journals maps, respectively. The labels represented the disciplines covered by the journal. The lines on the map started from the left and ended on the right, representing the citation links. There were three main citation paths shown on the map.

![The dual-map overlay of journals related to hepatocellular carcinoma research.\
There were three citation paths. The yellow path, papers published in immunology/biology journals mostly cited journals in biology/genetics area; the middle green path, papers published in medical/clinical journals partially cited journals in biology/genetics area; the bottom green path, papers published in medical/clinical journals partially cited journals in health/medicine area.](peerj-06-5477-g003){#fig-3}

Distribution of countries and institutes
----------------------------------------

The 24,331 papers in HCC research were contributed by 116 countries/regions ([Dataset S2](#supp-2){ref-type="supplementary-material"}). Extensive collaborations were observed between countries/regions ([Fig. 4A](#fig-4){ref-type="fig"}). According to the list of top 10 countries/regions ([Table 2](#table-2){ref-type="table"}) engaged in HCC research, China contributed the most publications (10,755), followed by the United States (3,993), Japan (3,296), and South Korea (1,937).

![The distribution of countries and institutes.\
(A) The network map of countries/regions that involved in hepatocellular carcinoma research. (B) The network map of institutes that involved in hepatocellular carcinoma research.](peerj-06-5477-g004){#fig-4}
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###### The top 10 countries and institutes contributed to publications in hepatocellular carcinoma research.
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  **Rank**   **Country/Region**   **Count**   **Institute**                        **Count**
  ---------- -------------------- ----------- ------------------------------------ -----------
  1          China                10,755      Fudan University                     1,029
  2          United States        3,993       Sun Yat-Sen University               813
  3          Japan                3,296       Second Military Medical University   692
  4          South Korea          1,937       Shanghai Jiao Tong University        527
  5          Taiwan               1,540       Zhejiang University                  475
  6          Italy                1,335       University of Hong Kong              383
  7          Germany              926         Seoul National University            380
  8          France               729         Yonsei University                    359
  9          England              452         Chinese University of Hong Kong      356
  10         Spain                433         Sungkyunkwan University              348

Nearly 11,000 institutes ([Dataset S3](#supp-3){ref-type="supplementary-material"}) made contributions to HCC research. The collaborations between institutes were not evident ([Fig. 4B](#fig-4){ref-type="fig"}), compared to countries. The top 10 institutes ([Table 2](#table-2){ref-type="table"}) contributed more than 20% of total publications. In the list, Fudan University ranked first, followed by Sun Yat-Sen University, Second Military Medical University and Shanghai Jiao Tong University.

Analysis of ESI top papers, H-index, and citations
--------------------------------------------------

Among the top four productive countries ([Fig. 5](#fig-5){ref-type="fig"}), the United States contributed the most number of ESI top papers (160) and achieved the highest H-index value (136). Due to a vast amount of literature, China owned the most citation counts (145,060). The other two countries, Japan and South Korea, did not have advantages in the ranking of the three items mentioned above.

![The distribution of ESI top papers, H-index, and citation (×0.001) in the top four countries.](peerj-06-5477-g005){#fig-5}

Distribution of authors
-----------------------

Over 55,900 authors ([Dataset S4](#supp-4){ref-type="supplementary-material"}) contributed to HCC research. [Figure 6A](#fig-6){ref-type="fig"} showed the collaboration network between authors. Among the top 10 contributive authors ([Table 3](#table-3){ref-type="table"}), Wang Y (297 publications) was ranked first, followed by Li J (291 publications), Zhang Y (279 publications) and Zhang J (264 publications).

![The distribution of authors.\
(A) The network map of active authors contributed to hepatocellular carcinoma research. (B) The network map of co-cited authors contributed to hepatocellular carcinoma research.](peerj-06-5477-g006){#fig-6}
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###### The top 10 authors, co-cited authors, and co-cited references in hepatocellular carcinoma research.

![](peerj-06-5477-g011)

  **Rank**   **Author**   **Count**   **Co-cited Author**   **Count**   **Co-cited Reference**                             **Count**
  ---------- ------------ ----------- --------------------- ----------- -------------------------------------------------- -----------
  1          Wang Y       297         Llovet JM             7,351       Bruix J, 2011, Hepatology, V53, P1020              1,730
  2          Li J         291         Bruix J               5,946       Jemal A, 2011, CA-Cancer J Clin, V61, P69          1,578
  3          Zhang Y      279         EL-Serag HB           5,038       Llovet JM, 2012, J Hepatol, V56, P908              1,206
  4          Zhang J      264         Parkin DM             2,769       Forner A, 2012, Lancet, V379, P1245                1,196
  5          Zhang L      254         Jemal A               2,363       Llovet JM, 2008, New Engl J Med, V359, P378        1,193
  6          Li Y         240         Poon RTP              2,042       Cheng AL, 2009, Lancet Oncol, V10, P25             855
  7          Fan J        237         Forner A              2,010       EL-Serag HB, 2011, New Engl J Med, V365, P1118     825
  8          Wang J       235         Mazaferro V           1,950       Torre LA, 2015, CA-Cancer J Clin, V65, P87         721
  9          Liu Y        226         Cheng AL              1,614       EL-Serag HB, 2007, Gastroenterology, V132, P2557   674
  10         Zhou J       225         Lencioni R            1,559       EL-Serag HB, 2012, Gastroenterology, V142, P1264   521

CiteSpace analysed the information of author citations and visualized it in a co-citation network ([Fig. 6B](#fig-6){ref-type="fig"}). Among the top 10 co-cited authors ([Table 3](#table-3){ref-type="table"}, [Fig. S2](#supp-6){ref-type="supplementary-material"}), Llovet JM (7,351 co-citations) was ranked first, followed by Bruix J (5,946 co-citations), EL-Serag HB (5,038 co-citations) and Parkin DM (2,769 co-citations).

Analysis of references
----------------------

We used CiteSpace IV to construct a network of co-cited references ([Fig. 7A](#fig-7){ref-type="fig"}) that revealed the relevance between papers. The values of Modularity Q and Mean Silhouette both were more than 0.5 ([Fig. S3](#supp-7){ref-type="supplementary-material"}), indicating that the distributivity and homogeneity of clusters were reasonable and acceptable. All clusters were named after terms extracted from the references of publications ([Fig. S4](#supp-8){ref-type="supplementary-material"}). In this network, the first massive cluster was named "\#0 meta-analysis", followed by the second, named "\#1 advanced hepatocellular carcinoma", and the third, named "\#2 second-line treatment." Furthermore, the timeline view of these clusters was shown in [Fig. 7B](#fig-7){ref-type="fig"}.

![The analysis of references.\
(A) The co-citation map of references from publications in hepatocellular carcinoma research. (B) The timeline view of co-cited references from publications in hepatocellular carcinoma research.](peerj-06-5477-g007){#fig-7}

Analysis of burst keywords
--------------------------

We identified keywords with strong citation bursts through CiteSpace IV ([Fig. 8](#fig-8){ref-type="fig"}, [Fig. S5](#supp-9){ref-type="supplementary-material"}). Among them, the keywords that had citation bursts after 2014 were listed as follows: "overexpression" (2014--2015), "delivery" (2014--2015), "cancer stem cell" (2015--2017), "epithelial-mesenchymal transition" (2015--2017), and "transarterial chemoembolization" (2015--2017).

![The keywords with the strong citation bursts in articles related to hepatocellular carcinoma research published from 2008 to 2017.](peerj-06-5477-g008){#fig-8}

Discussion
==========

General information
-------------------

At the beginning of the study, we searched for HCC-related papers published from 2000 to 2017 in the Web of Science. The overall trend of publications between 2000 and 2007 was stable, with only slowly increasing ([Fig. S6](#supp-10){ref-type="supplementary-material"}). The total number of publications during this period was relatively small, compared with the later period (2008--2017). For this study, we were committed to identify a trend that has obvious changes in the number of publications. Besides to including a sufficient number of articles, the time span cannot be too long, either, we finally determined to limit the search from 2008 onwards. In relation to the top 15 academic journals, two journals, *Hepatology* (IF 2016 = 13.246) and *Journal of Hepatology* (IF 2016 = 12.486) had an IF higher than 10; two others, *Oncotarget* (IF 2016 = 5.168) and *Cancer Letters* (IF 2016 = 6.375) had an IF between 10 and five; five journals, *World Journal of Gastroenterology* (IF 2016 = 3.365), *Tumor Biology* (IF 2016 = 3.650), *Journal of Gastroenterology and Hepatology* (IF 2016 = 3.452), *Liver International* (IF 2016 = 4.116), and *BMC Cancer* (IF 2016 = 3.288) had an IF between five and three. Furthermore, academic journals with a high IF (higher than three) accounted for 16.86% (*N* = 4,103) of total publications.

Among the top 10 contributive countries/regions in HCC research, China was the only one from the developing world, showing its vast progress in life science over the past decade. China had an absolute advantage in the number of papers published, which also received a large number of citations. However, the United States occupied the first positions in both ESI top papers and H-index. In terms of research quality, the United States was the dominant country in HCC research. The most active collaborations were observed between Saudi Arabia and Egypt, Australia and Scotland and England and Brazil. Moreover, the collaborations among European countries were much stronger than those among Asian countries.

The top 10 institutes contributed to 5,362 papers, which accounted for 22.03% of total publications. In this list, the top five institutes were all from China. Additionally, there were 3,994 Chinese institutes involved in HCC research ([Dataset S3](#supp-3){ref-type="supplementary-material"}), accounting for 36.34% of the total number of research institutes worldwide. According to recent reports, China accounted for more than half of world's HCC patients, including over 466,000 new cases in 2015 ([@ref-45]). The estimated incidence rate of HCC was 30.62 per 100,000 standard population, resulting it as the second common malignancy in China ([@ref-36]). Except for that, there are limited treatment options for unresectable HCC patients and the overall prognosis of HCC is very poor ([@ref-43]), making it a serious health issue in current China. That is the reason why a considerable number of Chinese institutes engaged in HCC research and China leads in the number of papers published.

Citation information
--------------------

Among the top 10 active authors, each person has published at least 225 papers; they were regarded as prolific authors. Despite that, none of them are included as top co-cited authors, suggesting that prolific authors should focus not only on number of publications but also quality of research. Regarding co-cited authors, those with more than 5,000 co-citations, including Llovet JM, who discovered the critical role of mTOR signaling in HCC pathogenesis ([@ref-40]), Bruix J, who provided guidelines for HCC management ([@ref-8]) and EL-Serag HB, who elaborated the epidemiology of HCC and viral hepatitis ([@ref-13]), have made significant contributions in this field.

The co-citation clusters in the timeline view demonstrated that top co-cited references were mainly gathered between 2008 and 2012. Meanwhile, among the top 100 co-cited references identified by CiteSpace IV, there were 72 items existed in the period from 2008 to 2012 ([Fig. S4](#supp-8){ref-type="supplementary-material"}). Given this result, the period (2008--2012) could be considered as a "golden phase" of HCC research within the past decade. [Table 3](#table-3){ref-type="table"} presented the top 10 co-cited references in HCC research. Bruix J (2011), who published a paper in *Hepatology*, had the highest co-citations (1730), followed by Jemal A (2011, 1,578 co-citations), Llovet JM (2012, 1,206 co-citations) and Forner A (2012, 1,196 co-citations), who published papers in *CA: A Cancer Journal for Clinicians*, *Journal of Hepatology* and *The Lancet* respectively. Additionally, other journals with highest impact factor have also contributed some papers on HCC research during the past decade ([Dataset S1](#supp-1){ref-type="supplementary-material"}), such as *New England Journal of Medicine* (5 papers), *The Lancet* (12 papers), *Nature* (10 papers), and *Cell* (nine papers). They were the fundamentals of this field.

Research frontiers
------------------

We used CiteSpace IV to capture the burst keywords, which could be considered a prediction of research frontiers. As shown in [Fig. 8](#fig-8){ref-type="fig"}, the blue line represented the time intervals and the red line represented the period of citation bursts. Here, we listed three frontiers of HCC research as follows:

1.  Transarterial chemoembolization: Transarterial chemoembolization (TACE) is considered as an effective treatment for intermediate or advanced HCC patients ([@ref-21]). In the United States, TACE is not only the most common therapy for HCC patients but also the most common bridging therapy for patients waitlisted for liver transplantation ([@ref-33]; [@ref-37]). According to a retrospective study of the SEER database, TACE utilization significantly improved survival for HCC patients, especially those at an intermediate stage ([@ref-20]). Additionally, a recent study has proved that TACE can be a useful treatment option for HCC patients with segmental portal vein tumour thrombus ([@ref-10]).

2.  Epithelial-mesenchymal transition: Epithelial-mesenchymal transition (EMT) is a biological process in which epithelial cells gradually change into a mesenchymal-like type ([@ref-39]). This process has proved to be involved in various pathological conditions, including inflammation, fibrosis and cancer ([@ref-6]; [@ref-34]). Increasing evidence demonstrated that EMT plays a vital role in transferring malignant hepatocytes during the progression of HCC ([@ref-19]; [@ref-23]; [@ref-29]). The association between EMT and HCC raises a demand to exploit novel diagnostic and therapeutic strategies against HCC progression.

3.  Cancer stem cell: Solid tumours contain a small fraction of tumorigenic cells, known as cancer stem cells (CSCs) ([@ref-38]). CSCs play a crucial role in tumour metastasis/recurrence and have been identified in many malignant tumours, including HCC ([@ref-38]). Accumulating studies have illustrated that HCC CSCs could be enriched by several different markers, including CD133, CD90, CD24, CD13 and EpCAM ([@ref-16]; [@ref-26]; [@ref-32]). HCC CSCs could partially explain the heterogeneity of HCC, metastasis after hepatic tumour resection and chemotherapeutic resistance in advanced HCC cells ([@ref-24]; [@ref-44]), which provide the potential to develop novel therapeutic strategies based on stem cell biology.

Strengths and limitations
-------------------------

To the best of our understanding, this paper is the first bibliometric analysis on HCC research trend over the past decade. The data analysis process was relatively objective. However, most publications retrieved from the database were written in English, causing incomplete analysis to some extent. Furthermore, this study consisted exclusively of original and review articles published between 2008 and 2017 and indexed by the Web of Science. It may not be enough to represent all HCC literature, such as other document types published in journals, books, and conferences were not included. The analysis in this study was based on articles recorded in the Science Citation Index-Expanded (SCI-E) of the Web of Science Core Collection (WoSCC). Each journal to which the SCI-E articles belong had its corresponding citation report provided by the Web of Science. Although other databases such as PubMed, Scopus, and Embase could provide a broader range of coverage, much of the "extra coverage" could be attributed to journals with potentially limited readers. Given that our objective was to conduct a high-quality bibliometric analysis to identify research trends in the core of HCC field, the SCI-E articles from WoSCC may be the only appropriate choice. Therefore, the results from other databases were not included. As for China ranked first in publications, except for the active participation of Chinese institutes, the strong support of science funding in China could be another important reason. A recent study has shown that the proportion of funded papers in China is the highest, compared to other countries. Nearly 80% of SCI-E papers are supported by science funding ([@ref-35]). Therefore, the advantage of the number of publications from China is particularly prominent, which may create an illusion that the gap between western countries and China is widening. Finally, although the Web of Science database is still updating, this study covers the vast majority of papers in HCC research since 2008; new data may not influence the final results.

Conclusions
===========

The number of publications in HCC research has been increasing over the past decade. The United States, Japan, and China were the top three countries contributing to HCC studies. There were active collaborations between developed countries. Although many Chinese institutes were engaged in HCC research, the United States was still the dominant country. Llovet JM, Bruix J and EL-Serag HB may be ideal candidates for academic cooperation. Transarterial chemoembolization, epithelial-mesenchymal transition and cancer stem cell may be frontiers in this field, and researchers should pay close attention to relevant studies in the coming years.
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